Novavax Sweden
As Novavax continues to maximize the impact of our proven technology platform, our team in Sweden plays a critical role in advancing our Matrix adjuvant through R&D and manufacturing. Novavax Sweden has been part of Novavax since 2013, when the Company acquired Isconova, a spinoff from the Swedish University of Agricultural Sciences.
Core Capabilities
- Innovating through new formulations of Matrix adjuvants
- Manufacturing, QC and supplying adjuvants for human and veterinary use
- Supporting partnerships that leverage our technology to advance other companies’ best-in-class medicines.
Our Matrix-M adjuvant enhances the body's immune response in a targeted and efficient way, significantly improving both the magnitude and the duration of immune response.1
Combining Novavax’s protein-based nanoparticles with our Matrix-M adjuvant achieves strong, long-lasting and broad immune responses.1
Powering Progress:
Pipeline, Partners & Sustainability
Pipeline
We are advancing a pipeline of high-value assets targeting areas with unmet medical need, strong scientific rationale and significant commercial potential.
Partnerships
Our strategy is to create partnership and collaboration opportunities to maximize the impact and value of our pipeline assets and Matrix-M adjuvant alone.
Sustainability
We focus our sustainability efforts on four strategic pillars which guide us to make a positive impact in global health and operate in an environmentally sustainable and inclusive manner.
Amplify your Career in Uppsala
The Novavax Sweden team seeks to build a site that attracts and retains the best talent to support our global corporate strategy. We help to ensure our people thrive in and out of the office, providing resources to help employees grow and succeed.
Contact
- Stertman L. et al.; The Matrix-M™ adjuvant: A critical component of vaccines for the 21st century. Hum Vaccin Immunother. 2023 Dec 31;19(1):2189885. doi: 10.1080/21645515.2023.2189885.